Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

Paul Matte; Michel Ducreux

doi:10.1159/000530402

Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

Paul Matte, Michel Ducreux

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.

Original language	English
Pages (from-to)	480-483
Number of pages	4
Journal	Case Reports in Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1159/000530402
Publication status	Published - 3 Jul 2023

Keywords

Antineoplastic agents
Capecitabine
Rectal cancer
Toxicity
Vision loss

Access to Document

10.1159/000530402

Cite this

@article{456eff4f059540baac5a2960cdb3772d,

title = "Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind",

abstract = "Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.",

keywords = "Antineoplastic agents, Capecitabine, Rectal cancer, Toxicity, Vision loss",

author = "Paul Matte and Michel Ducreux",

note = "Publisher Copyright: {\textcopyright} 2023 2023 The Author(s).Published by S. Karger AG, Basel ",

year = "2023",

month = jul,

day = "3",

doi = "10.1159/000530402",

language = "English",

volume = "16",

pages = "480--483",

journal = "Case Reports in Oncology",

issn = "1662-6575",

number = "1",

}

TY - JOUR

T1 - Case Report

T2 - Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

AU - Matte, Paul

AU - Ducreux, Michel

PY - 2023/7/3

Y1 - 2023/7/3

N2 - Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.

AB - Capecitabine is an orally administered fluoropyrimidine carbamate antineoplastic agent, widely used to treat different tumor types. Eye toxicity is not well established with this type of drug. Here, we report the case of a 57-year-old man with a low rectal cancer whose vision decreased 3 weeks after starting a daily treatment of capecitabine and radiotherapy. After eliminating all other diagnoses, toxicity of antineoplastic agents remains the most likely hypothesis, making it the first case of vision loss induced by this capecitabine.

KW - Antineoplastic agents

KW - Capecitabine

KW - Rectal cancer

KW - Toxicity

KW - Vision loss

UR - http://www.scopus.com/inward/record.url?scp=85165935888&partnerID=8YFLogxK

U2 - 10.1159/000530402

DO - 10.1159/000530402

M3 - Article

AN - SCOPUS:85165935888

SN - 1662-6575

VL - 16

SP - 480

EP - 483

JO - Case Reports in Oncology

JF - Case Reports in Oncology

IS - 1

ER -

Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind

Abstract

Keywords

Access to Document

Other files and links

Cite this